Methyl Coclaurine

Methyl Coclaurine

SCHEMBL1627504

COc1cc2c(cc1O)[C@H](Cc1ccc(O)cc1)N(C)CC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.86
ALDH1A1 P00352 2/20 0.86
HSD17B10 Q99714 2/20 0.86
ALOX15 P16050 1/20 0.86
DRD2 P14416 1/20 0.83
DRD1 P21728 1/20 0.83
BCHE P06276 1/20 0.74
ACHE P22303 1/20 0.74
KCNH2 Q12809 2/20 0.74
LMNA P02545 2/20 0.68
MAPK1 P28482 2/20 0.68
CYP2D6 P10635 1/20 0.68
TP53 P04637 1/20 0.65
TSHR P16473 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl Coclaurine SCHEMBL29373409 1.00 KDM4E (0.86) KDM4EALDH1A1HSD17B10ALOX15DRD2
Methyl Coclaurine SCHEMBL12807819 1.00 KDM4E (0.86) KDM4EALDH1A1HSD17B10ALOX15DRD2
Methyl Coclaurine SCHEMBL18179206 1.00 KDM4E (0.86) KDM4EALDH1A1HSD17B10ALOX15DRD2
Methyl Coclaurine SCHEMBL29365454 1.00 KDM4E (0.86) KDM4EALDH1A1HSD17B10ALOX15DRD2
SCHEMBL12807694 0.95 KDM4E (0.86) KDM4EALDH1A1HSD17B10ALOX15DRD2
SCHEMBL29202140 0.93 KDM4E (1.00) KDM4EALDH1A1HSD17B10ALOX15DRD2
SCHEMBL29787915 0.93 KDM4E (1.00) KDM4EALDH1A1HSD17B10ALOX15DRD2
SCHEMBL1389166 0.93 KDM4E (1.00) KDM4EALDH1A1HSD17B10ALOX15DRD2
SCHEMBL29373104 0.92 DRD2 (0.89) KDM4EALDH1A1HSD17B10ALOX15DRD2
SCHEMBL30803078 0.91 BCHE (0.85) KDM4EALDH1A1HSD17B10ALOX15DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240240194-A1 TRANSCRIPTION FACTOR SUN PHARMACEUTICAL INDUSTRIES AUSTRALIA PTY LIMITED (AU) 2024-07-18 US claimed
EP-4347846-A1 TRANSCRIPTION FACTOR Sun Pharmaceutical Industries Australia PTY Limited (AU) 2024-04-10 EP claimed
WO-2022249068-A1 TRANSCRIPTION FACTOR SUN PHARMACEUTICAL INDUSTRIES AUSTRALIA PTY LIMITED (AU) 2022-12-01 WO claimed
US-11427827-B2 Engineered benzylisoquinoline alkaloid epimerases and methods of producing benzylisoquinoline alkaloids ANTHEIA, INC. (US) 2022-08-30 US claimed
US-20190194269-A1 POLYNUCLEOTIDES AND POLYPEPTIDES USEFUL FOR MAKING ALKALOID COMPOUNDS INTREXON CORPORATION (US) 2019-06-27 US claimed
US-20260103736-A1 Methods Of Improving Production Of Morphinan Alkaloids And Derivatives ANTHEIA INC (US) 2026-04-16 US disclosed
US-12497638-B2 Methods of producing epimerases and benzylisoquinoline alkaloids THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2025-12-16 US disclosed
EP-4594342-A2 METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES Antheia, Inc. (US) 2025-08-06 EP disclosed
US-20250137021-A1 METHODS OF PRODUCING NOR-OPIOID AND NAL-OPIOID BENZYLISOQUINOLINE ALKALOIDS HERCULES CAPITAL, INC., AS AGENT 2025-05-01 US disclosed
US-12180525-B2 Methods of producing nor-opioid and nal-opioid benzylisoquinoline alkaloids ANTHEIA, INC. (US) 2024-12-31 US disclosed
US-12173035-B2 Polynucleotides and polypeptides useful for making alkaloid compounds ANTHEIA, INC. (US) 2024-12-24 US disclosed
US-20240240194-A1 TRANSCRIPTION FACTOR SUN PHARMACEUTICAL INDUSTRIES AUSTRALIA PTY LIMITED (AU) 2024-07-18 US disclosed
EP-1632565-A1 Modulation of alkaloid biosynthesis in plants and plants having altered alkaloid biosynthesis JOHNSON & JOHNSON RESEARCH PTY LIMITED (AU) 2006-03-08 EP disclosed
EP-1053303-A4 CYTOCHROME P450 REDUCTASES FROM POPPY PLANTS JOHNSON & JOHNSON RES PTY LTD (AU) 2005-10-19 EP disclosed
EP-1402037-A1 PLANT GENES INVOLVED IN DEFENSE AGAINST PATHOGENS Syngenta Participations AG (CH) 2004-03-31 EP disclosed
EP-1368484-A2 PLANT GENES, THE EXPRESSION OF WHICH ARE ALTERED BY PATHOGEN INFECTION Syngenta Participations AG (CH) 2003-12-10 EP disclosed
WO-2003000898-A1 PLANT GENES INVOLVED IN DEFENSE AGAINST PATHOGENS SYNGENTA PARTICIPATIONS AG (CH) 2003-01-03 WO disclosed
WO-2002022675-A2 PLANT GENES, THE EXPRESSION OF WHICH ARE ALTERED BY PATHOGEN INFECTION SYNGENTA PARTICIPATIONS AG (CH) 2002-03-21 WO disclosed
EP-1053303-A1 CYTOCHROME P450 REDUCTASES FROM POPPY PLANTS JOHNSON & JOHNSON RESEARCH PTY LIMITED (AU) 2000-11-22 EP disclosed
WO-1999011765-A1 CYTOCHROME P450 REDUCTASES FROM POPPY PLANTS JOHNSON & JOHNSON RESEARCH PTY. LIMITED (AU) 1999-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12173035-B2 Polynucleotides and polypeptides useful for making alkaloid compounds TARBP1, RNMT, RRP1B KDM4E 4388/4885ALDH1A1 4597/4885HSD17B10 4423/4885
US-20260103736-A1 Methods Of Improving Production Of Morphinan Alkaloids And Derivatives OPRK1, OPRM1, OPRD1 KDM4E 3363/4885ALDH1A1 476/4885HSD17B10 60/4885
US-20190194269-A1 POLYNUCLEOTIDES AND POLYPEPTIDES USEFUL FOR MAKING ALKALOID COMPOUNDS TARBP1, RNMT, RRP1B KDM4E 4388/4885ALDH1A1 4597/4885HSD17B10 4423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.